Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Halozyme Therapeutics today announced a global collaboration and non-exclusive license agreement with fellow US biotech Acumen Pharmaceuticals. 6 November 2023
Australian inflammatory diseases specialist Dimerix has received an initial payment of 6.5 million euros ($7 million) in line with the recently-announced license agreement with Advanz Pharma. 6 November 2023
In another antibody-drug conjugate (ADC) deal for the US pharma major, Bristol Myers Squibb has acquired USA and South Korea-based Orum Therapeutics’ ORM-6151 program. 6 November 2023
UK-based biotech Roquefort Therapeutics has announced that its mesodermal killer (MK) cell program has reached a significant milestone. 6 November 2023
Swiss biotech MoonLake Immunotherapeutics has announced positive top-line results from its global Phase II ARGO trial evaluating the efficacy and safety of the Nanobody sonelokimab in patients with active psoriatic arthritis (PsA). 6 November 2023
Swiss biotech Idorsia yesterday released further data for aprocitentan, the firm’s investigational dual endothelin receptor antagonist for the treatment of patients with resistant hypertension, at the American Society of Nephrology (ASN) Kidney Week 2023. 4 November 2023
Lexeo Therapeutics has announced the final pricing of its initial public offering of 9,090,910 shares of common stock at a price to the public of $11.00 per share. 3 November 2023
Independent French drugmaker Pierre Fabre has expanded a global partnership for Ebvallo (tabelecleucel) with US biotech Atara Biotherapeutics. 3 November 2023
San Diego, USA-based precision medicine firm Kura Oncology’s shares rose 4% to $8.31 yesterday, after it announced a research collaboration with Mirati Therapeutics. 3 November 2023
US ophthalmic drug developer Aldeyra Therapeutics saw its shares leap 48.5% to $2.54 yesterday after it announced the signing of a deal with pharma major AbbVie 2 November 2023
US ophthalmic drug developer Ocuphire Pharma has appointed Dr George Magrath, as chief executive and member of the board of directors, effective today. 2 November 2023
French biotech Cellectis saw its shares rocket 149% to 2.24 euros by mid-afternoon trading today, on news of a collaboration an investment deal with UK pharm major AstraZeneca. 1 November 2023
UK clinical-stage biotech STORM Therapeutics, which is targeting RNA modifying enzymes (RMEs) for oncology and other diseases, has appointed Marguerite Hutchinson as its chief business officer. 1 November 2023
California, USA-based chimeric antigen receptor (CAR) T-cell therapies developer ImmPACT Bio has appointed Han Lee as president and chief financial officer (CFO). 1 November 2023
Danish biotech company Evaxion has announced initial results from a Phase II trial of the first five metastatic melanoma patients treated with EVX-01, a peptide-based personalized cancer vaccine. 31 October 2023
US biotech Beam Therapeutics today announced that Eli Lilly has agreed to acquire certain rights under Beam’s amended collaboration and license agreement with Verve Therapeutics. 31 October 2023
Gilead Sciences Kite unit has agreed a collaboration and research deal with Epicrispr Biotechnologies (Epic Bio), using the latter’s proprietary gene regulation platform to develop next-generation cancer cell therapies. 31 October 2023